January 2024 Top Biopharma Deal Upfront
January 2024 Top Biopharma Deal Upfront
January 7, 2024
$4,165M
$185M
–
–
$3.98B in option exercise fees, development, regulatory, and commercial milestones.
Undisclosed royalties
–
Phase I RNA-based therapy with an option for up to 2 additional therapies for the treatment of cardiovascular diseases
Development and Commercialization License
Collaborative Development, No Shared Cost; Options to Add Products, TAs, and/or Territories
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive